Organization
Sun Yat-sen University Cancer Centre
7 abstracts
Abstract
Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial.Org: Sun Yat-sen University Cancer Centre, Collaborative Innovation Centre for Cancer Medicine, Hunan Cancer Hospital, Department of Radiation Oncology, Affiliated Hospital of Guizhou Medical University,
Abstract
Efficacy and safety of the vebreltinib in patients with previously treated, secondary glioblastoma/IDH mutant glioblastoma with PTPRZ1-METFUsion GENe (FUGEN): A randomised, multicentre, open-label, phase II/III trial.Org: Beijing Neurosurgical Institute, Capital Medical University, Department of Neurosurgery, Prince of Wales Hospital, Beijing Tiantan Hospital, The First Affiliated Hospital of Zhengzhou University,
Abstract
Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.Org: Sun Yat-sen University Cancer Center, Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Centre, Department of Oncology, National Taiwan University Hospital, Affiliated Hospital of Guizhou Medical University,
Abstract
A phase II study of anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinomar (A-Plus trial): Updated efficacy and safety.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.Org: Sun Yat-sen University Cancer Centre, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine,
Abstract
Prospective study of integrating post-radiotherapy [18F] fluorodeoxyglucose-positron emission tomography/computed tomography scan and plasma Epstein-Barr virus DNA in surveillance of locoregionally advanced nasopharyngeal carcinoma.Org: Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Centre for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
A pilot phase II trial of neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin (NeoCPC) for locoregionally advanced, resectable squamous cell carcinoma of the head and neck.Org: Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Department of Otolaryngology Head and Neck Surgery, The Fifth Affiliated Hospital of Guangzhou Medical University,